Monopar Therapeutics
ALXN1840
Wilson disease
Resolved
7days ago
FDA decision · Jun 30, 2026
What's at stake
The FDA's approval decision on ALXN1840 for Wilson disease is due Jun 30, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 15h ago
“The Company remains on track with its plans to submit the New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in mid-2026.”